Neuralstem ALS trial principal investigator to speak at Brookings Institution

June 05, 2010

ROCKVILLE, Maryland, June 4, 2010 - Neuralstem, Inc. (NYSE Amex: CUR) announced that Dr. Eva Feldman, the Principal Investigator of its Phase I clinical trial to treat ALS (Amyotrophic Lateral Sclerosis, or Lou Gehrig's disease) with its spinal cord stem cells, will present at the inaugural A. Alfred Taubman Forum on Improving Science and Technology Innovation in the United States, on June 8, 2010, at The Brookings Institution in Washington, D.C. Dr. Feldman, PhD, MD, is the Russell DeJong Professor of Neurology and Director of the ALS Clinic, University of Michigan.

Dr. Feldman's 10:00 AM talk will address the importance of medical research at academic centers to keep America at the forefront of innovation, of which the ALS trial is an example. As part of the talk, she will discuss some general aspects of the trial, which will evaluate the safety of Neuralstem's spinal cord stem cells and the transplantation procedure in up to 18 patients.
-end-
For more information on the event, please go to: http://www.brookings.edu/events/2010/0608_science_technology.aspx.

About Neuralstem, Inc.

Neuralstem's patented technology enables, for the first time, the ability to produce neural stem cells of the human brain and spinal cord in commercial quantities, and the ability to control the differentiation of these cells into mature, physiologically relevant human neurons and glia. The company is targeting major central nervous system diseases including: Ischemic Spastic Paraplegia, Traumatic Spinal Cord Injury, Huntington's disease and Amyotrophic Lateral Sclerosis (ALS), often referred to as Lou Gehrig's disease. ALS is a progressive fatal neurodegenerative disease that affects nerve cells in the brain, leading to the degeneration and death of the motor neurons in the spinal cord that control muscle movement. Neuralstem is in a Phase I clinical trial to treat ALS. For more information, please go to www.neuralstem.com.

Cautionary Statement Regarding Forward Looking Information

This news release may contain forward-looking statements made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements in this press release regarding potential applications of Neuralstem's technologies constitute forward-looking statements that involve risks and uncertainties, including, without limitation, risks inherent in the development and commercialization of potential products, uncertainty of clinical trial results or regulatory approvals or clearances, need for future capital, dependence upon collaborators and maintenance of our intellectual property rights. Actual results may differ materially from the results anticipated in these forward- looking statements. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in Neuralstem's periodic reports, including the annual report on Form 10-K for the year ended December 31, 2009 and the quarterly report on Form 10-Q for the quarter ended March 31, 2010

Neuralstem, Inc.

Related Medical Research Articles from Brightsurf:

Patients say ask before using medical records for research
A new study led by Michigan Medicine researchers finds that even when patients understand the overall benefit to society, they still want to be able to give consent at least once before their de-identified data is used for research.

Most patients willing to share medical records for research purposes
In a survey, UC San Diego researchers report most patients are willing to share medical records for research purposes, with a few caveats.

Tax hurts investment in medical device research and development
New Iowa State University research shows companies cut funding for research and development in response to a tax imposed on medical devices as part of the Affordable Care Act.

Centralized infrastructure facilitates medical education research
The Council of Academic Family Medicine Educational Research Alliance has enabled a large number of research teams to conduct meaningful scholarship with a fraction of the usual time and energy.

Sex, gender, or both in medical research
Only a minority of medical studies take sex and gender into account when analyzing and reporting research results.

Research!America to honor medical and health research advocacy leaders
Research!America's 21st annual Advocacy Awards will honor outstanding advocates for research whose contributions to health and medicine have saved lives and improved quality of life for patients worldwide.

Ohioans say it is important for the state to lead in education and medical research
An overwhelming majority of Ohio residents say it is important for the state to be a leader in education (89 percent) and in medical and health research (87 percent), according to a state-based public opinion survey commissioned by Research!America.

Medical research influenced by training 'genealogy'
By analyzing peer-reviewed scientific papers that examined the effectiveness of a surgical procedure, researchers at University of California, San Diego School of Medicine provide evidence suggesting that the conclusions of these studies appear to be influenced by the authors' mentors and medical training.

Diversity in medical research is a long way off, study shows
Despite Congressional mandates aimed at diversifying clinical research, little has changed in the last 30 years in both the numbers of studies that include minorities and the diversity of scientists being funded, according to a new analysis by researchers at UCSF.

Research!America to honor leaders in medical and health research advocacy
Research!America's 20th annual Advocacy Awards will honor exceptional advocates for research whose achievements in their fields have brought hope to patients worldwide.

Read More: Medical Research News and Medical Research Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.